bone incretin hormones perceiver or receiver骨肠促胰岛素激素感知者或接收者.pdfVIP

Hindawi Publishing Corporation Experimental Diabetes Research Volume 2012, Article ID 519784, 5 pages doi:10.1155/2012/519784 Review Article Bone: Incretin Hormones Perceiver or Receiver? Ilaria Dicembrini,1 Edoardo Mannucci,2 and Carlo Maria Rotella1 1 Section of Endocrinology, Department of Clinical Pathophysiology, Careggi Teaching Hospital, University of Florence and Obesity Agency, 50127 Florence, Italy 2 Careggi Teaching Hospital, Diabetes Agency, 50127 Florence, Italy Correspondence should be addressed to Carlo Maria Rotella, c.rotella@dfc.unifi.it Received 6 March 2012; Accepted 9 May 2012 Academic Editor: Giovanni Di Pasquale Copyright © 2012 Ilaria Dicembrini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Novel incretin-based drugs, such as glucagon-like peptide-1 receptor agonists (GLP-1 RA) and dipeptidyl peptidase-4 inhibitors (DPP-4i), have been last introduced in the pharmacological treatment of type 2 diabetes. In the last few years, the interest on the relationship of gut hormones with bone metabolism in diabetes has been increasing. The aim of present paper is to examine in vitro and in vivo evidence on the connections between incretin hormones and bone metabolism. We also discuss results of clinical trials and metaanalysis, explore the effects of incretin drugs in vitro on osteogenic cells and osteoclasts, and speculate on the possibility of different effects of GLP-1 RA and DPP-4i on the risk of bone fractures risk in humans. Although existing preliminary evidence suggests a protective effect on the bone, at least for DPP-4i, further controlled, long-term stu